Breaking News
Get 40% Off 0
🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought it Read More
Close

DBV Technologies (DBV)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.99 0.00    0.10%
11:35:18 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  France
ISIN:  FR0010417345 
  • Volume: 78,908
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.99 - 1.00
DBV Technologies 0.99 0.00 0.10%

DBV User Rankings

 
Users ranking according to the performance of their sentiments for the DBV Technologies stock.
RankUsernameTotalClosedWinningWin %Chg. %
1Victor El Del Muelle98450+983.82%
2Xavier Gasser111100+581.8%
3Zaouch walid111100+555.37%
4Luca Challine111100+530.58%
5Frederic DIEU111100+527.24%
6Thierry GRUNEISEN33266.67+512.63%
7bastien fraisse111100+500.51%
8喜如 吴111100+491.8%
9Pascal Vermersch88562.5+464.55%
10Jf SIROT222100+453.88%
11Daniel deSaintDenis111100+440.46%
12David BESSEAU111100+433.15%
13fred bey22150+421.52%
14Gatta NDIONE44375+367.77%
15louis richard111100+353.83%
16Maxence Baudet111100+339.67%
17Fabrice Raynal111100+337.72%
18Fabrice Lagrange111100+325.14%
19Folie Christopher22150+315.99%
20Fred Lacoste111100+315.88%
21laurent pouppeville111100+309.83%
22Guigui Cardi55480+253%
23José Sánchez77457.14+132.81%
24Hugo Solvet111100+118.22%
25ALEXIS MARSAUDON111100+87.75%
26Jonathan Gauchet111100+87.75%
27Matthieu Merit111100+74.06%
28gilles viellet111100+57.39%
29Charlez Ghilardi111100+48.02%
30Mat Bonnef111100+34.47%
31Thierry JACOB33266.67+29.93%
32Julien Kergonou111100+29.18%
33Vince Kedge55240+29.15%
34Davide Leone111100+26.34%
35Baptiste De Barba111100+26.3%
36Brice Ferrand111100+26.1%
37Stephane Phuket111100+25.04%
38Loic Dagniaux111100+24.72%
39Tiago Da Cruz111100+22.96%
40Paul Champ22150+22.9%
41giaqui lam111100+20.78%
42jorge nunes111100+19.48%
43Dominique Bousquet55360+18.85%
44Gilles Lefebvre111100+17.58%
45Christophe Thiebeaux111100+16.58%
46Patrick Weissenburger22150+15.5%
47Fabien Chosalland222100+14.23%
48Sébastien Lé111100+14.15%
49marc duport111100+13.49%
50philippe cousyn111100+13.35%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DBV Comments

Write your thoughts about DBV Technologies
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
João Catarino
João Catarino Feb 11, 2021 11:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://finance.yahoo.com/news/notice-media-covid-19-july-120000875.html?.tsrc=fin-srch
Krava Tsakosh
Krava Tsakosh Jan 18, 2021 8:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA will approve it...
Krava Tsakosh
Krava Tsakosh Jan 18, 2021 8:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
DBV Technologies price target raised to $7 from $4 at Goldman Sachs. Goldman Sachs analyst Graig Suvannavejh raised the firm's price target on DBV Technologies (DBVT) to $7 from $4 and keeps a Buy rating on the shares after the company announced an update on the U.S. regulatory status of lead asset Viaskin Peanut. The stock closed Friday up 51% to $5.66. The analyst came away "increasingly positive" given the clarity gained on the forward, and continues to have confidence in the ultimate approvability of Viaskin Peanut in the U.S. and its commercial potential. Viaskin Peanut is the more attractive and easier product to administer relative to its main competition, Nestle's (NSRGY) Palforzia, Suvannavejh tells investors in a research note.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email